1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Escoubas, P. Bernard, C. Lazdunski, M. Darbon, H. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Protein Sci. PRCIEI 0795 0961-8368 12 1332 1343 10.1110/ps.0307003 12824480 Recombinant production and solution structure of PcTx1, the specific peptide inhibitor of ASIC1a proton-gated cation channels 2003 10.2210/pdb1lmm/pdb pdb_00001lmm 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 4705.513 Psalmotoxin 1 1 man polymer PcTx1 no no EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n Trinidad chevron tarantula Psalmopoeus Escherichia sample 179874 Psalmopoeus cambridgei 562 Escherichia coli database_2 pdbx_nmr_software pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Data collection Database references Derived calculations 1 0 2003-11-25 1 1 2008-04-28 1 2 2011-07-13 1 3 2022-02-23 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_nmr_software.name RCSB Y RCSB 2002-05-02 REL structures with the lowest energy 30 20 DQF-COSY 2D TOCSY 2D NOESY DQF-COSY 2D TOCSY 2D NOESY 3.6 ambient 283 K 3.6 ambient 300 K distance geometry, simulated annealing 2.9 mm collection XwinNMR 2.6 processing XwinNMR 2.6 Bartels data analysis XEASY 1.3 Gnthert structure solution DIANA 2.8 Brunger refinement CNS 1.1 500 Bruker DRX GLU 1 n 1 GLU 1 A ASP 2 n 2 ASP 2 A CYS 3 n 3 CYS 3 A ILE 4 n 4 ILE 4 A PRO 5 n 5 PRO 5 A LYS 6 n 6 LYS 6 A TRP 7 n 7 TRP 7 A LYS 8 n 8 LYS 8 A GLY 9 n 9 GLY 9 A CYS 10 n 10 CYS 10 A VAL 11 n 11 VAL 11 A ASN 12 n 12 ASN 12 A ARG 13 n 13 ARG 13 A HIS 14 n 14 HIS 14 A GLY 15 n 15 GLY 15 A ASP 16 n 16 ASP 16 A CYS 17 n 17 CYS 17 A CYS 18 n 18 CYS 18 A GLU 19 n 19 GLU 19 A GLY 20 n 20 GLY 20 A LEU 21 n 21 LEU 21 A GLU 22 n 22 GLU 22 A CYS 23 n 23 CYS 23 A TRP 24 n 24 TRP 24 A LYS 25 n 25 LYS 25 A ARG 26 n 26 ARG 26 A ARG 27 n 27 ARG 27 A ARG 28 n 28 ARG 28 A SER 29 n 29 SER 29 A PHE 30 n 30 PHE 30 A GLU 31 n 31 GLU 31 A VAL 32 n 32 VAL 32 A CYS 33 n 33 CYS 33 A VAL 34 n 34 VAL 34 A PRO 35 n 35 PRO 35 A LYS 36 n 36 LYS 36 A THR 37 n 37 THR 37 A PRO 38 n 38 PRO 38 A LYS 39 n 39 LYS 39 A THR 40 n 40 THR 40 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N GLU 22 A N GLU 22 A O VAL 34 A O VAL 34 1 -3.38 0.50 120.30 116.92 A A A NE CZ NH2 ARG ARG ARG 13 13 13 N 2 -3.35 0.50 120.30 116.95 A A A NE CZ NH2 ARG ARG ARG 13 13 13 N 6 -3.10 0.50 120.30 117.20 A A A NE CZ NH2 ARG ARG ARG 13 13 13 N 10 -3.34 0.50 120.30 116.96 A A A NE CZ NH2 ARG ARG ARG 13 13 13 N 12 -3.58 0.50 120.30 116.72 A A A NE CZ NH2 ARG ARG ARG 13 13 13 N 13 -3.25 0.50 120.30 117.05 A A A NE CZ NH2 ARG ARG ARG 13 13 13 N 19 -3.41 0.50 120.30 116.89 A A A NE CZ NH2 ARG ARG ARG 13 13 13 N 1 A VAL 11 -41.19 159.64 1 A ASN 12 75.20 83.36 1 A ARG 13 83.21 -16.71 1 A HIS 14 51.61 87.10 1 A CYS 17 -42.91 150.45 1 A CYS 18 -70.13 -96.35 1 A GLU 19 -61.89 -154.53 1 A ARG 26 -74.64 -159.69 1 A SER 29 -57.53 177.53 1 A PHE 30 -66.04 -167.14 1 A LYS 36 -54.15 -78.28 1 A PRO 38 -92.67 -88.93 1 A LYS 39 -70.27 -78.60 2 A VAL 11 -53.58 86.10 2 A ASN 12 175.41 81.11 2 A HIS 14 45.98 71.19 2 A CYS 17 -47.25 151.83 2 A CYS 18 -67.81 -97.22 2 A GLU 19 -62.87 -155.03 2 A ARG 28 -100.78 -68.11 2 A PHE 30 -70.25 -152.67 2 A LYS 36 -48.73 -76.19 2 A PRO 38 -65.23 71.42 3 A ASP 2 -60.34 86.27 3 A LYS 6 -59.88 -170.18 3 A ASN 12 59.50 18.92 3 A CYS 18 -69.96 -93.11 3 A GLU 19 -61.41 -159.60 3 A SER 29 -58.88 171.25 3 A PHE 30 -68.60 -157.39 4 A VAL 11 -58.97 82.02 4 A ASN 12 177.46 75.16 4 A HIS 14 48.28 84.10 4 A CYS 18 -55.35 -94.71 4 A GLU 19 -66.64 -154.94 4 A ARG 27 -70.49 -73.05 4 A PHE 30 -63.06 -147.11 4 A PRO 38 -75.38 -70.14 5 A CYS 3 -70.16 -95.47 5 A VAL 11 -60.47 82.35 5 A ASN 12 177.59 81.50 5 A HIS 14 46.23 83.63 5 A CYS 18 -70.24 -88.57 5 A GLU 19 -67.88 66.47 5 A ARG 28 -95.98 -82.15 5 A PHE 30 -70.25 -153.66 5 A VAL 34 -170.33 138.16 5 A LYS 36 -48.15 -89.51 5 A LYS 39 -63.61 82.65 6 A VAL 11 -67.60 70.26 6 A ASN 12 -177.22 -70.51 6 A HIS 14 53.63 92.41 6 A CYS 18 -70.40 -83.31 6 A GLU 19 -63.79 -153.29 6 A PHE 30 -60.48 -158.15 6 A PRO 38 -80.12 -75.35 7 A CYS 3 -62.35 -176.66 7 A ASN 12 -177.32 -54.38 7 A HIS 14 52.26 84.88 7 A CYS 17 -51.58 172.63 7 A CYS 18 -64.62 -96.70 7 A GLU 19 -65.78 -164.89 7 A ARG 26 -116.53 -168.18 7 A ARG 27 -70.15 -76.16 7 A PHE 30 -69.94 -82.10 7 A THR 37 -47.10 104.94 7 A PRO 38 -63.57 -157.03 8 A VAL 11 -59.05 87.84 8 A ASN 12 -176.84 78.82 8 A HIS 14 44.24 83.04 8 A CYS 17 -57.76 179.63 8 A CYS 18 -68.99 -95.12 8 A GLU 19 -63.91 -155.80 8 A ARG 28 -92.51 -75.94 8 A SER 29 -68.13 -176.11 8 A PHE 30 -70.10 -149.02 8 A VAL 32 -170.11 144.81 8 A LYS 36 -64.66 -131.54 9 A CYS 3 -59.20 177.11 9 A VAL 11 -57.42 85.51 9 A ASN 12 179.76 80.91 9 A CYS 18 -70.03 -105.76 9 A GLU 19 -60.23 -161.47 9 A ARG 27 -70.02 -79.70 9 A PHE 30 -70.04 -156.42 10 A ASP 2 -63.50 82.31 10 A LYS 6 -96.02 30.81 10 A TRP 7 -148.21 29.30 10 A ASN 12 172.96 -36.88 10 A CYS 18 -60.31 -85.64 10 A GLU 19 -70.34 -161.89 10 A ARG 28 -70.32 -80.96 10 A PHE 30 -57.59 -80.03 10 A VAL 32 -170.28 142.21 10 A VAL 34 -173.18 137.55 10 A LYS 36 -60.34 -78.94 10 A PRO 38 -88.16 -77.87 11 A ASP 2 -67.17 74.13 11 A PRO 5 -53.80 171.78 11 A TRP 7 -147.99 29.32 11 A ASN 12 68.88 84.53 11 A ARG 13 76.39 82.32 11 A HIS 14 -67.48 49.74 11 A CYS 17 -69.73 -159.81 11 A CYS 18 -70.31 -105.29 11 A GLU 19 -70.43 -160.46 11 A ARG 28 -101.57 -70.99 11 A PHE 30 -69.96 -155.64 11 A LYS 39 -53.66 -177.63 12 A ASP 2 -65.86 77.55 12 A CYS 3 -59.43 172.67 12 A ASN 12 -153.89 -86.87 12 A HIS 14 53.81 79.22 12 A CYS 18 -56.98 -103.36 12 A GLU 19 -63.97 -157.19 12 A ARG 26 -78.99 -168.45 12 A ARG 28 -133.71 -42.30 12 A SER 29 -59.07 173.03 12 A PHE 30 -61.95 -167.45 12 A LYS 36 -70.14 -100.22 12 A PRO 38 -84.20 42.34 13 A VAL 11 -49.79 89.50 13 A ASN 12 173.61 84.49 13 A ARG 13 46.11 27.71 13 A CYS 17 -57.10 177.23 13 A CYS 18 -70.17 -108.24 13 A GLU 19 -63.66 -152.25 13 A ARG 28 -85.88 -86.62 13 A SER 29 -70.39 -164.16 13 A PHE 30 -70.10 -154.26 13 A LYS 36 -67.29 -81.31 13 A PRO 38 -73.47 -154.04 13 A LYS 39 -52.76 106.16 14 A ASP 2 -59.11 87.35 14 A LYS 6 -88.99 39.81 14 A TRP 7 -150.22 22.35 14 A ASN 12 -178.64 -56.01 14 A CYS 17 -53.35 170.57 14 A CYS 18 -63.43 -123.94 14 A GLU 19 -46.77 91.81 14 A ARG 28 -89.04 -71.89 14 A PHE 30 -69.99 -146.47 14 A LYS 36 -70.26 -111.31 14 A LYS 39 -64.30 -73.41 15 A LYS 6 -95.19 38.51 15 A TRP 7 -156.86 27.99 15 A VAL 11 -100.60 71.88 15 A ASN 12 -176.83 -62.55 15 A HIS 14 55.70 87.20 15 A CYS 18 -59.61 -102.60 15 A GLU 19 -63.30 -157.59 15 A ARG 28 -79.02 -71.91 15 A PHE 30 -70.24 -145.19 15 A LYS 36 -69.23 -102.76 16 A PRO 5 -53.46 96.18 16 A LYS 6 -45.76 151.26 16 A VAL 11 -69.02 69.25 16 A ASN 12 -177.97 80.13 16 A HIS 14 42.34 79.43 16 A CYS 18 -55.71 -105.04 16 A GLU 19 -57.28 -155.96 16 A ARG 27 -70.27 -71.52 16 A ARG 28 -70.88 -76.42 16 A PHE 30 -57.07 -79.97 16 A LYS 39 -66.59 75.79 17 A ASP 2 -59.76 93.93 17 A CYS 3 -70.42 -169.84 17 A VAL 11 -67.39 68.68 17 A ASN 12 -169.95 76.74 17 A HIS 14 49.04 82.96 17 A CYS 18 -61.84 -96.38 17 A GLU 19 -62.56 -154.22 17 A ARG 27 -70.22 -78.51 17 A ARG 28 -62.39 -73.39 17 A PHE 30 -69.07 -81.10 17 A PRO 38 -69.42 -161.28 18 A ASP 2 -59.26 105.43 18 A LYS 6 -55.52 -172.38 18 A VAL 11 -68.51 72.50 18 A ASN 12 -176.23 78.23 18 A HIS 14 47.13 83.93 18 A CYS 18 -59.22 -100.64 18 A GLU 19 -70.13 -161.65 18 A PHE 30 -70.08 -166.74 18 A LYS 39 -59.59 -74.85 19 A ASP 2 -66.15 93.36 19 A CYS 3 -70.29 -84.87 19 A PRO 5 -59.63 98.37 19 A TRP 7 64.29 75.68 19 A ASN 12 -176.90 78.60 19 A CYS 18 -67.47 -98.10 19 A GLU 19 -61.33 -155.12 19 A ARG 28 -81.49 -81.97 19 A SER 29 -69.83 -179.84 19 A PHE 30 -69.96 -81.23 20 A PRO 5 -61.12 93.76 20 A VAL 11 -68.20 63.05 20 A ASN 12 174.34 83.11 20 A ARG 13 70.38 76.28 20 A CYS 17 -49.91 176.67 20 A CYS 18 -55.37 -101.79 20 A ARG 28 -105.30 -67.43 20 A PHE 30 -70.05 -162.23 20 A LYS 39 -62.70 86.45 Solution Structure of Psmalmotoxin 1, the First Characterized Specific Blocker of ASIC1a NA+ channel 1 N N disulf 2.031 A CYS 3 A SG CYS 3 1_555 A CYS 18 A SG CYS 18 1_555 disulf 2.030 A CYS 10 A SG CYS 10 1_555 A CYS 23 A SG CYS 23 1_555 disulf 2.032 A CYS 17 A SG CYS 17 1_555 A CYS 33 A SG CYS 33 1_555 TOXIN ICK, TOXIN TXP1_PSACA UNP 1 1 P60514 1 40 1LMM 1 40 P60514 A 1 1 40 2 anti-parallel A GLU 22 A GLU 22 A LYS 25 A LYS 25 A GLU 31 A GLU 31 A VAL 34 A VAL 34